Tissue Culture Core Facility The goal of the this core is to provide UNC Lineberger Comprehensive Cancer Center members with expert services and quality controlled and innovative materials required for basic and clinical research involving in vitro cell culture and related testing services. This core provides services and support not found elsewhere at UNC. The facility has two main "divisions." The first is Cell Culture, with all of its services, products, and testing. Services are designed and implemented to cover a wide range of user needs, such as large scale cell and metabolite production from cell propagation, monoclonal antibody (Mab) production using standard procedures, and production of gram quantities of Mab using hollow fiber, bioreactor and membrane designed units. Many ofthe Mabs produced are serum- and protein-free and can be used without further concentration or purification. Cell cryopreservation services are available using a programmable rate freezer. Testing for sterility, endotoxin, and mycoplasma are routinely provided. The other "division" of the core focuses on clinical support through its immortalization of human B-cells using EBV. This area is being increased to Include cell line identification by fingerprinting and karyotyping where required. The facility is led by Stephen Oglesbee, Director, with over 34 years of direct experience. The Core adds value to the Center by providing a range of specialized services, centralized functions, and cost savings and convenience. Highlights of research supported by the core include: high human B-cell transformation rates (over 98%) and the development and testing of new specialized media either already licensed or soon to be managed for the good ofthe UNC LCCC. There are currently >900 cell lines kept on site. Peer-reviewed members (159) account for 80% of the total facility use. In 2009,172 cancer center members (all but 13 are peer -reviewed) from all programs used the core. Future plans include expansion of its human B-cell immortalization program in support of numerous projects with other methods of immortalization of other cell types. Cell line fingerprinting is becoming a newly added service. CCSG funds of $66,895 are requested, representing 5% of total operating costs.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016086-38
Application #
8594161
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2013-12-01
Budget End
2014-11-30
Support Year
38
Fiscal Year
2014
Total Cost
$170,210
Indirect Cost
$66,183
Name
University of North Carolina Chapel Hill
Department
Type
DUNS #
608195277
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
Joseph, Sarah B; Arrildt, Kathryn T; Sturdevant, Christa B et al. (2015) HIV-1 target cells in the CNS. J Neurovirol 21:276-89
Sikov, William M; Berry, Donald A; Perou, Charles M et al. (2015) Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (A J Clin Oncol 33:13-21
Blazer, Marlo; Wu, Christina; Goldberg, Richard M et al. (2015) Neoadjuvant modified (m) FOLFIRINOX for locally advanced unresectable (LAPC) and borderline resectable (BRPC) adenocarcinoma of the pancreas. Ann Surg Oncol 22:1153-9
Knight, E R W; Patel, E Y; Flowers, C A et al. (2015) ASC deficiency suppresses proliferation and prevents medulloblastoma incidence. Oncogene 34:394-402
Dellon, Evan S; Speck, Olga; Woodward, Kimberly et al. (2015) Distribution and variability of esophageal eosinophilia in patients undergoing upper endoscopy. Mod Pathol 28:383-90
Qi, Qibin; Kilpeläinen, Tuomas O; Downer, Mary K et al. (2014) FTO genetic variants, dietary intake and body mass index: insights from 177,330 individuals. Hum Mol Genet 23:6961-72
Jha, Deepak Kumar; Strahl, Brian D (2014) An RNA polymerase II-coupled function for histone H3K36 methylation in checkpoint activation and DSB repair. Nat Commun 5:3965
Guo, Shutao; Lin, C Michael; Xu, Zhenghong et al. (2014) Co-delivery of cisplatin and rapamycin for enhanced anticancer therapy through synergistic effects and microenvironment modulation. ACS Nano 8:4996-5009
Clark, Martha A; Goheen, Morgan M; Spidale, Nicholas A et al. (2014) RBC barcoding allows for the study of erythrocyte population dynamics and P. falciparum merozoite invasion. PLoS One 9:e101041
Zhang, Weihe; DeRyckere, Deborah; Hunter, Debra et al. (2014) UNC2025, a potent and orally bioavailable MER/FLT3 dual inhibitor. J Med Chem 57:7031-41

Showing the most recent 10 out of 292 publications